Available online at ajdhs.com

Asian Journal of Dental and Health Sciences

Open Access to Dental and Medical Research

Copyright  © 2025 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

 

The Mentzer Index in Maternal Anemia: An Early Diagnostic Marker

Emmanuel Ifeanyi Obeagu *

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe

 

 

Introduction

Maternal anemia is a prevalent and significant health concern, particularly during pregnancy, affecting millions of women worldwide. It is associated with numerous maternal and fetal complications, including preterm birth, low birth weight, fatigue, and in severe cases, maternal mortality. The condition is most commonly caused by iron deficiency anemia (IDA), but thalassemia trait (TT), a hereditary blood disorder, is also a significant contributor, especially in regions where it is endemic. Both IDA and TT can lead to microcytic anemia, which can present with similar clinical features, making it challenging to differentiate between the two based on clinical signs alone. An accurate and early diagnosis is critical to ensure appropriate management and prevent adverse outcomes for both mother and child.^1-2 Iron deficiency anemia during pregnancy occurs due to increased iron requirements for fetal growth and maternal blood volume expansion. It can be effectively managed with iron supplementation, which is the cornerstone of treatment for this condition. On the other hand, thalassemia trait, a genetic condition that results in abnormal hemoglobin production, does not respond to iron supplementation and can lead to unnecessary iron overload if treated incorrectly. Misdiagnosing thalassemia trait as IDA and administering iron unnecessarily can cause harm, including iron toxicity, and delay the proper diagnosis and treatment. Thus, differentiating between these two types of anemia is critical to providing the correct therapeutic approach.^3-4 The Mentzer Index (MI) is a simple, cost-effective, and widely used diagnostic tool designed to assist clinicians in differentiating between IDA and thalassemia trait. The MI is calculated by dividing the mean corpuscular volume (MCV) by the red blood cell (RBC) count. An MI value of less than 13 is typically indicative of thalassemia trait, while a value greater than 13 suggests iron deficiency anemia. This straightforward formula has made the MI a valuable tool in routine clinical practice, particularly in settings where access to advanced diagnostic techniques, such as hemoglobin electrophoresis, may be limited.⁵

The utility of the Mentzer Index lies in its ability to provide a rapid and inexpensive preliminary diagnosis of microcytic anemia, especially in populations at high risk for thalassemia. In many cases, it can offer sufficient guidance for initial treatment decisions, enabling clinicians to either begin iron supplementation for IDA or avoid unnecessary iron therapy for patients with thalassemia trait. However, despite its ease of use and accessibility, the Mentzer Index is not without limitations. It can be less reliable in cases of mixed anemia or when the patient has multiple underlying causes of anemia. Furthermore, it is not effective in diagnosing other types of anemia, such as those caused by vitamin deficiencies or chronic disease.^6-7 In addition to its diagnostic utility, the Mentzer Index has important implications for maternal anemia management in pregnancy. Timely and accurate diagnosis using the MI can significantly reduce the risk of maternal and fetal complications associated with misdiagnosis. For instance, by differentiating between IDA and thalassemia trait, clinicians can avoid unnecessary iron therapy, which could lead to iron overload and other complications in TT. Moreover, the MI can guide clinicians in deciding when to seek further diagnostic tests, such as serum ferritin levels, hemoglobin electrophoresis, or genetic testing for thalassemia, ensuring that the appropriate management plan is developed for each patient.^8-9 Despite its advantages, there are challenges and limitations associated with the use of the Mentzer Index in clinical practice. It is most effective in cases where the underlying cause of anemia is either IDA or thalassemia trait, but its usefulness may be compromised in situations involving mixed anemia or other complicating factors. Additionally, the MI can yield ambiguous results in patients with conditions like anemia of chronic disease or lead poisoning, where other diagnostic approaches would be required. Given these constraints, it is essential to use the MI as part of a broader diagnostic framework, complementing it with additional tests to ensure a comprehensive and accurate diagnosis of anemia in pregnancy.^10-11

Application of the Mentzer Index in Maternal Anemia

Maternal anemia is a common and significant health issue during pregnancy, with potential risks to both maternal and fetal well-being. The most prevalent types of anemia during pregnancy are iron deficiency anemia (IDA) and thalassemia trait (TT), both of which can present with microcytic anemia. Differentiating between these two conditions is crucial, as they require different management strategies. The Mentzer Index (MI), a simple and cost-effective diagnostic tool, plays an important role in this differentiation, especially in settings where more advanced testing may not be accessible.^12-13 In pregnancy, the Mentzer Index is particularly useful for distinguishing between IDA and TT in women who present with microcytic anemia. IDA is typically treated with iron supplementation, whereas thalassemia trait does not respond to iron and requires a different management approach. By calculating the ratio of the mean corpuscular volume (MCV) to red blood cell (RBC) count, the MI provides a preliminary screening tool. If the MI is greater than 13, the diagnosis points to iron deficiency anemia, suggesting that iron supplementation should be the first line of treatment. In contrast, an MI less than 13 suggests a thalassemia trait, which does not require iron therapy but may need genetic counseling and monitoring.^14-15

The MI is particularly beneficial in low-resource settings where other diagnostic methods, such as serum ferritin levels or hemoglobin electrophoresis, may not be readily available. It allows clinicians to quickly assess whether iron deficiency or thalassemia is the likely cause of the anemia, facilitating timely interventions and avoiding the unnecessary administration of iron in women with thalassemia trait. Additionally, the MI can serve as a useful tool in prenatal care programs, helping to identify women at risk of anemia early in their pregnancy, enabling appropriate treatment and reducing the likelihood of complications such as preterm birth, low birth weight, or maternal fatigue.^16-17 Despite its practical applications, the Mentzer Index is not a definitive diagnostic test. It is best used as an initial screening tool, with further diagnostic tests recommended for confirmation. For instance, if the MI suggests thalassemia trait, confirmatory tests such as hemoglobin electrophoresis or genetic testing are necessary to establish the diagnosis. Similarly, if the MI indicates IDA, additional tests, including serum ferritin and total iron binding capacity (TIBC), can help confirm iron deficiency. The MI also has limitations in cases of mixed anemia, anemia of chronic disease, or when other underlying conditions contribute to the microcytic anemia. In such cases, a more comprehensive diagnostic approach is needed.^18-19

Benefits of the Mentzer Index in Maternal Anemia Diagnosis

The Mentzer Index (MI) offers several key advantages when used for the diagnosis of maternal anemia, particularly in differentiating between iron deficiency anemia (IDA) and thalassemia trait (TT). Its simplicity, cost-effectiveness, and ease of use make it an invaluable tool, especially in resource-limited settings, where access to advanced diagnostic tests may be constrained. Here are some of the primary benefits of the Mentzer Index in the diagnosis of maternal anemia:

The Mentzer Index is a straightforward, rapid diagnostic tool that can be easily calculated using basic laboratory results—mean corpuscular volume (MCV) and red blood cell (RBC) count. This makes it an efficient screening tool, particularly in settings where more complex testing might not be feasible. The formula can be calculated without specialized equipment, making it accessible for clinicians in both rural and urban healthcare settings.²⁰

One of the key benefits of the MI is its ability to differentiate between two common causes of microcytic anemia in pregnancy: iron deficiency anemia (IDA) and thalassemia trait (TT). Since these two conditions require different management strategies, identifying the underlying cause of anemia early is crucial. An MI greater than 13 typically indicates IDA, which can be treated with iron supplementation, while an MI less than 13 suggests thalassemia trait, which does not benefit from iron supplementation but may require genetic counseling and follow-up care. This early differentiation helps avoid unnecessary iron treatment and ensures proper management, reducing the risks of complications.²¹

 

The MI is an affordable diagnostic tool, which makes it particularly advantageous in low- and middle-income countries or resource-poor settings where advanced diagnostic tools like hemoglobin electrophoresis or serum ferritin testing may not be readily available. By using the MI, clinicians can make a more informed decision regarding anemia management without the need for expensive or sophisticated equipment, thus making anemia management more accessible to a broader population of pregnant women.²¹

Incorporating the Mentzer Index into prenatal care helps to identify women at risk of anemia early in pregnancy. Early detection allows for timely intervention, which can prevent the adverse outcomes associated with untreated anemia, such as preterm birth, low birth weight, maternal fatigue, or developmental complications in the fetus. By using the MI, healthcare providers can implement more effective anemia screening protocols, leading to better overall maternal and fetal health outcomes.²²

The MI helps reduce the risk of misdiagnosing anemia and, consequently, over-treating pregnant women. For instance, iron supplementation is ineffective and potentially harmful in cases of thalassemia trait, as excess iron can lead to iron overload. By identifying the underlying cause of anemia through the MI, clinicians can avoid unnecessary iron administration, thus preventing the side effects of iron therapy, such as gastrointestinal discomfort or iron toxicity, and ensuring that patients receive the most appropriate treatment.²³

The Mentzer Index not only aids in identifying the type of anemia but also guides subsequent management strategies. In cases of iron deficiency, the MI can prompt clinicians to initiate iron supplementation or dietary interventions. Conversely, in cases of thalassemia trait, the MI helps to avoid unnecessary iron treatment while focusing on long-term monitoring and genetic counseling. This targeted approach ensures more effective and personalized care for pregnant women, improving the overall healthcare experience and maternal outcomes.²⁴

Limitations and Challenges

While the Mentzer Index (MI) offers significant benefits in diagnosing maternal anemia, particularly in differentiating between iron deficiency anemia (IDA) and thalassemia trait (TT), it is not without its limitations and challenges. It is essential for healthcare providers to be aware of these potential drawbacks to ensure the MI is used appropriately and effectively as part of a comprehensive diagnostic approach. Below are some of the key limitations and challenges associated with the MI:

The MI is primarily designed to differentiate between IDA and thalassemia trait, both of which commonly present as microcytic anemia. However, in cases where a pregnant woman has mixed anemia (e.g., a combination of IDA and anemia of chronic disease or other underlying conditions), the MI may not be reliable. Mixed anemias can present with overlapping clinical and laboratory features, leading to an ambiguous MI result that cannot definitively point to a single cause. This makes it challenging to rely solely on the MI in such cases, necessitating further diagnostic testing to accurately identify the underlying etiology of the anemia.²⁵

Pregnancy induces a variety of physiological changes that can affect the results of the MI. For example, the increased plasma volume during pregnancy can lead to a dilutional effect, reducing the red blood cell count (RBC), which may result in a lower MI value. This dilution effect can sometimes complicate the interpretation of the MI, as it may not accurately reflect the actual RBC concentration or MCV, especially in the first and second trimesters when pregnancy-induced hemodilution is most pronounced. Therefore, the MI should be interpreted with caution, especially in early pregnancy, as the physiological changes may impact the precision of the result.²⁶

While the MI can help differentiate between IDA and TT, it is not a definitive diagnostic tool. The MI should be considered as a preliminary screening test rather than a conclusive diagnostic method. For instance, while a low MI (less than 13) strongly suggests thalassemia trait, confirmation of thalassemia requires more specific tests such as hemoglobin electrophoresis or genetic testing. Similarly, if the MI indicates iron deficiency anemia, further tests like serum ferritin, total iron-binding capacity (TIBC), or transferrin saturation are necessary for confirmation. Relying solely on the MI without additional confirmatory tests may lead to misdiagnosis and suboptimal management.²⁷

The MI is most effective in differentiating between two causes of microcytic anemia (IDA and TT). However, it does not account for other forms of anemia that might present with similar symptoms, such as anemia of chronic disease or vitamin B12 and folate deficiency anemia. These conditions may present with normocytic or macrocytic anemia and may not be adequately detected through the MI. In such cases, additional testing beyond the MI is necessary to identify the underlying cause of the anemia and provide the most appropriate treatment.²⁵

While the MI is a valuable screening tool, there is potential for misinterpretation, especially if the calculated MI value is close to the threshold of 13. For example, women with conditions such as mild anemia of chronic disease or those in the early stages of iron deficiency might present with MI values that fall into a grey area, making it difficult to distinguish between IDA and thalassemia. In such cases, healthcare providers may need to rely on clinical judgment, patient history, and additional laboratory tests to refine the diagnosis and avoid unnecessary treatments.²⁶

The accuracy of the MI may vary based on population-specific genetic factors, particularly in regions where thalassemia is more prevalent. Different populations may exhibit variations in RBC count and MCV that can affect the MI calculation. For example, in populations with a high prevalence of thalassemia traits or other hemoglobinopathies, the MI might not always be as reliable in predicting the correct diagnosis. Genetic differences in RBC size and volume could skew the MI results, limiting its generalizability across diverse populations. In such cases, confirmatory tests like hemoglobin electrophoresis or DNA analysis are essential to accurately diagnose thalassemia.²⁷

Conclusion

The Mentzer Index (MI) is a useful, cost-effective, and accessible tool for differentiating between iron deficiency anemia (IDA) and thalassemia trait (TT) in pregnant women. Its ability to provide a quick and easy diagnostic aid, particularly in resource-limited settings, makes it an invaluable screening tool for maternal anemia. By offering early differentiation between these two common causes of microcytic anemia, the MI supports timely and appropriate management, helping to reduce unnecessary treatments like iron supplementation, which could be harmful in cases of thalassemia trait.

Conflict of Interest: Author declares no potential conflict of interest with respect to the contents, authorship, and/or publication of this article.

Source of Support: Nil

Funding: The authors declared that this study has received no financial support.

Informed Consent Statement: Not applicable. 

Data Availability Statement: The data supporting in this paper are available in the cited references. 

Ethics approval: Not applicable.

References

1. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. The American journal of clinical nutrition. 2016; 103(2):495-504. https://doi.org/10.3945/ajcn.115.107896 PMid:26739036

2. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-18. https://doi.org/10.22270/ijmspr.v10i2.95

3. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.

4. Petrakos G, Andriopoulos P, Tsironi M. Pregnancy in women with thalassemia: challenges and solutions. International journal of women's health. 2016:441-451. https://doi.org/10.2147/IJWH.S89308 PMid:27660493 PMCid:PMC5019437

5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 Apr;9(4):145-148.

6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. Journal of Public Health and Nutrition. 2023;6(1):138.

7. Arora S, Rana D, Kolte S, Dawson L, Dhawan I. Validation of new indices for differentiation between iron deficiency anemia and beta thalessemia trait, a study in pregnant females. International Journal of Scientific Reports. 2018; 4(2):26. https://doi.org/10.18203/issn.2454-2156.IntJSciRep20180394

8. Obeagu EI, Obeagu GU, Insights into Maternal Health: Mentzer Index for Early Anemia Detection, International Journal of Medical Sciences and Pharma Research,2024;10(4):44-49 https://doi.org/10.22270/ijmspr.v10i4.122

9. Obeagu EI, Influence of Hemoglobin Variants on Vaso-Occlusive Phenomena in Sickle Cell Anemia: A Review, International Journal of Medical Sciences and Pharma Research, 2024;10(2):54-59 https://doi.org/10.22270/ijmspr.v10i2.104

10. Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, Aguilar Martinez P, Bou‐Fakhredin R, Muckenthaler MU, Unal S, Porto G. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. Hemasphere. 2024; 8(7):e108. https://doi.org/10.1002/hem3.108 PMid:39011129 PMCid:PMC11247274

11. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Apr 19;2(2):1-9.

12. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58

13. Sahli CA, Bibi A, Ouali F, Fredj SH, Dakhlaoui B, Othmani R, Laouini N, Jouini L, Ouenniche F, Siala H, Touhami I. Red cell indices: differentiation between β-thalassemia trait and iron deficiency anemia and application to sickle-cell disease and sickle-cell thalassemia. Clinical Chemistry and Laboratory Medicine (CCLM). 2013; 51(11):2115-24. https://doi.org/10.1515/cclm-2013-0354 PMid:23800659

14. Hoffmann JJ, Nabbe KC, van den Broek NM. Effect of age and gender on reference intervals of red blood cell distribution width (RDW) and mean red cell volume (MCV). Clinical Chemistry and Laboratory Medicine (CCLM). 2015; 53(12):2015-9. https://doi.org/10.1515/cclm-2015-0155 PMid:26536583

15. Miftahussurur M, Husada D, Ningtyas WS. Association Association Of Shine and Lal Index Β-Thalassemia Trait Screening Results with Anaemia and Low Birth Weigh. International Journal of Nursing And Midwifery Science (IJNMS). 2023; 7(3):290-296. https://doi.org/10.29082/IJNMS/2023/Vol7/Iss3/543

16. Shahid H, Saleem M, Naseer N, Tabussam S, Aziz A, Ullah S. Evaluation of Srivastava index to distinguishing Beta-Thalassemia Trait from Iron Deficiency. Pakistan Journal of Medical & Health Sciences. 2022;16(05):1225. https://doi.org/10.53350/pjmhs221651225

17. Vehapoglu A, Ozgurhan G, Demir AD, Uzuner S, Nursoy MA, Turkmen S, Kacan A. Hematological indices for differential diagnosis of Beta thalassemia trait and iron deficiency anemia. Anemia. 2014; 2014(1):576738. https://doi.org/10.1155/2014/576738 PMid:24818016 PMCid:PMC4003757

18. Urrechaga E. Discriminant value of% microcytic/% hypochromic ratio in the differential diagnosis of microcytic anemia. Clinical chemistry and laboratory medicine. 2008;46(12):1752-1758. https://doi.org/10.1515/CCLM.2008.355 PMid:19055451

19. Obeagu EI, Obeagu GU, Anemia in Pregnancy: Mentzer Index as a Predictor for Iron Supplementation Needs, International Journal of Medical Sciences and Pharma Research, 2024;10(4):39-43 https://doi.org/10.22270/ijmspr.v10i4.121

20. Obeagu EI, Obeagu GU. Sickle cell anaemia in pregnancy: a review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13. https://doi.org/10.22270/ijmspr.v10i2.103

21. Obeagu EI, Ubosi NI, Uzoma G. Antioxidant Supplementation in Pregnancy: Effects on Maternal and Infant Health. Int. J. Adv. Multidiscip. Res. 2023;10(11):60-70.

22. Obeagu EI, Obeagu GU. Mitigating Oxidative Stress in Pregnancy through Antioxidant Supplementation: A Narrative Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(9):7-17.

23. Obeagu EI, Obeagu GU. Enhancing Maternal and Fetal Well-being: The Role of Antioxidants in Pregnancy. Elite Journal of Medical Sciences. 2024;2(4):76-87.

24. Obeagu EI, Obeagu GU. Antioxidant Supplementation and Prevention of Early Pregnancy Loss: A Narrative Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(9):28-37. https://doi.org/10.22270/ijmspr.v10i4.120

25. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7):25-28. https://doi.org/10.19080/JGWH.2023.25.556169

26. Obeagu EI, Obeagu GU. Hypoxia-induced Metabolic Changes in Pregnancy: Clinical Perspectives. Elite Journal of Medicine. 2024;2(8):50-59.

27. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):67-80.